Fighting Cancer with Real-Time Diagnostics

Inadequate real-time tissue assessment of biopsies from different cell types, like cancer cells, immune cells, granuloma, and others, forces proceduralists, such as bronchoscopists and radiologists, to choose between intraprocedural partial tissue adequacy assessment, rapid on-site evaluation (ROSE), or sending tissue samples for full pathology review. Neither truly answers the question, “Do we have enough cells to submit to pathology for the best chance of a conclusive diagnosis?” This can lead to prolonged delay for patient results, the need for a redo procedure, and potential delays for treatment options for the patient.